fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Vanda Pharmaceuticals agrees with the FDA on resubmission of the application for Hetlioz for the treatment of patients with Smith-Magenis syndrome.

Written by | 14 May 2020

Vanda Pharmaceuticals Inc. announced that following the completion of a Type A Meeting with the FDA on 8 May 2020, it has reached agreement with the FDA to… read more.

Positive topline data from phase III study of omidubicel in patients with high-risk hematologic malignancies- Gamida Cell

Written by | 14 May 2020

Gamida Cell Ltd.:announced positive topline results from its Phase III clinical study evaluating the safety and efficacy of omidubicel, an investigational advanced cell therapy in development as a… read more.

Three-year data from CheckMate -227 confirms durable, long-term survival benefit for Opdivo + Yervoy in metastatic first-line non-small cell lung cancer .- BMS

Written by | 14 May 2020

Bristol Myers Squibb announced three-year follow-up results from Part 1 of the Phase III CheckMate -227 trial , demonstrating that Opdivo (nivolumab) plus Yervoy (ipilimumab) provided sustained improvements… read more.

Opdivo + Yervoy with limited chemotherapy significantly improves overall survival vs. chemotherapy alone for first-line metastatic non-small cell lung cancer in CheckMate -9LA study.- BMS

Written by | 14 May 2020

Bristol Myers Squibb announced the first presentation of results from the Phase III CheckMate -9LA trial, which demonstrated a statistically significant and clinically meaningful survival benefit with Opdivo… read more.

Health Canada approves first COVID-19 serological test for use in the country to detect COVID-19 antibodies. DiaSorin

Written by | 14 May 2020

Health Canada says it has authorized the first COVID-19 serological test for use in the country to detect antibodies specific to the virus. DiaSorin, an Italian multinational biotechnology… read more.

NIH clinical trial testing antiviral remdesivir plus anti-inflammatory baricitinib for COVID-19 begins.

Written by | 13 May 2020

A randomized, controlled clinical trial evaluating the safety and efficacy of a treatment regimen of the investigational antiviral remdesivir plus the anti-inflammatory drug baricitinib for coronavirus disease 2019… read more.

Sarclisa + carfilzomib + dexamethasone phase III IKEMA trial meets primary endpoint early in patients with relapsed multiple myeloma.- Sanofi

Written by | 13 May 2020

The Phase III IKEMA clinical trial evaluating Sarclisa (isatuximab) added to carfilzomib and dexamethasone met the primary endpoint at its first planned interim analysis, demonstrating significantly prolonged progression-free… read more.

Phase III EXPLORER-HCM trial of MYK 461 meets all endpoints in hypertrophic cardiomyopathy.- MyoKardia

Written by | 13 May 2020

MyoKardia announced positive topline data from the company’s Phase III pivotal EXPLORER-HCM clinical trial of MYK 461 (mavacamten) for the treatment of patients with symptomatic, obstructive hypertrophic cardiomyopathy… read more.

FDA gives emergency use authorisation for SARS-CoV-2 IgG test for COVID-19 diagnostics.- Abbott

Written by | 12 May 2020

Abbott announced that the FDA issued Emergency Use Authorization (EUA) for the company’s SARS-CoV-2 IgG lab-based serology blood test on the Alinity i system. Abbott plans to ship… read more.

Phase III BRIDGE trial of PRX 102 met main objectives for safety and efficacy in Fabry disease.- Protalix BioTherapeutics

Written by | 12 May 2020

Protalix BioTherapeutics announced positive topline results from its Phase III BRIDGE clinical trial of PRX 102 (pegunigalsidase alfa), the Company’s plant cell-expressed recombinant, PEGylated, cross-linked alpha-galactosidase-A product candidate… read more.

Results from interim analysis of RESOLVE-IT phase III trial of elafibranor in adults with NASH and fibrosis. Genfit

Written by | 12 May 2020

Genfit announced results from an interim analysis of the RESOLVE-IT Phase III trial evaluating once-daily, 120mg of elafibranor in adults with non-alcoholic steatohepatitis (NASH). The trial did not… read more.

FDA grants emergency use authorization to the Zero Contact COVID-19 test kit as a saliva-based diagnostic for at home use to detect COVID-19.- Vitagene

Written by | 11 May 2020

Vitagene has announced the availability of 50,000 FDA authorized at home Zero-Contact or Saliva-based COVID-19 test kits for use during the current public emergency to detect COVID-19. Vitagene… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.